jetcityimage
- Eli Lilly (NYSE:LLY) has put the brakes on a phase 2a study examining bimagrumab, a drug to prevent muscle wasting, a common issue with quick weight loss, in combination with its obesity drug Zepbound (tirzepatide).
- A notice on the study’s